Literature DB >> 1280771

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

M J Alter1, H S Margolis, K Krawczynski, F N Judson, A Mares, W J Alexander, P Y Hu, J K Miller, M A Gerber, R E Sampliner.   

Abstract

BACKGROUND: Chronic liver disease develops in more than half of patients with post-transfusion hepatitis C, but little is known about the natural history of community-acquired hepatitis C.
METHODS: In 1985 and 1986 we identified adults with acute non-A, non-B hepatitis in four counties in the United States and followed them prospectively. We used three markers to detect hepatitis C virus (HCV) infection in stored samples of serum: antibody to HCV (anti-HCV) detected by second-generation serologic assays; HCV RNA detected by polymerase-chain-reaction assay; and antibody to HCV antigen (anti-HCVAg) detected by fluorescent-antibody-blocking assay.
RESULTS: Of 130 patients with non-A, non-B hepatitis, 106 (82 percent) had HCV infection, 93 were positive for anti-HCV, and 13 were positive only for HCV RNA or anti-HCVAg. Chronic hepatitis developed in 60 (62 percent) of 97 HCV-infected patients followed for 9 to 48 months, with no relation to the risk factors for infection. Ten of the 30 patients who had liver biopsies had chronic active hepatitis. In samples collected 42 to 48 months after the onset of hepatitis, HCV RNA was detected in 12 of 13 tested patients with chronic hepatitis and in all 15 tested patients with hepatitis that had resolved. Anti-HCV persisted in all but two of the initially positive patients, for a rate of antibody loss of 0.6 per 100 person-years.
CONCLUSIONS: Patients with community-acquired hepatitis C have a high rate of chronic hepatitis. HCV may be a major cause of chronic liver disease in the United States, and in most patients HCV infection seems to persist for at least several years, even in the absence of active liver disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280771     DOI: 10.1056/NEJM199212313272702

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  318 in total

1.  Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study.

Authors:  A R Osella; L Sonzogni; A Cavallini; L Foti; V Guerra; A Di Leo; M U Mondelli; G Misciagna; E M Silini
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 3.  Hepatitis C in childhood.

Authors:  F Bortolotti
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

Review 4.  Hepatitis C: universal or selective screening?

Authors:  R P Brettle
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

5.  Natural variation in translational activities of the 5' nontranslated RNAs of hepatitis C virus genotypes 1a and 1b: evidence for a long-range RNA-RNA interaction outside of the internal ribosomal entry site.

Authors:  M Honda; R Rijnbrand; G Abell; D Kim; S M Lemon
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans.

Authors:  S M Lemon; H Lerat; S A Weinman; M Honda
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

7.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

8.  HCV infection should be managed in specialist centres.

Authors:  J L Brown
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

9.  Hepatitis C virus infection in cocaine users--a silent epidemic.

Authors:  H H Harsch; J Pankiewicz; A S Bloom; C Rainey; J K Cho; L Sperry; E A Stein
Journal:  Community Ment Health J       Date:  2000-06

10.  Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides.

Authors:  R Zhang; J Durkin; W T Windsor; C McNemar; L Ramanathan; H V Le
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.